Literature DB >> 34854954

H. pylori CagA activates the NLRP3 inflammasome to promote gastric cancer cell migration and invasion.

XiaoYi Zhang1,2, Chao Li1,2, Yuan Xie3,4, Dingyu Chen1,5, XiaoFeng He1,5, Yan Zhao1,5, LiYa Bao6, Qingrong Wang1,5, JianJiang Zhou7,8,9.   

Abstract

OBJECTIVE: The CagA (cytotoxin-related gene A, CagA) protein is an important factor for the pathogenicity of Helicobacter pylori (H. pylori). Although H. pylori has previously been shown to activate the NLRP3 inflammasome, it remains unclear what role CagA plays in this process. In the current study, we aimed to investigate the effect of CagA on NLRP3 activation and how it is linked to gastric cancer cell migration and invasion.
METHODS: CagA positive H. pylori strain (Hp/CagA+) and CagA gene knockout mutant (Hp/ΔCagA) infected and the pcDNA3.1/CagA plasmid transfected gastric epithelial cell lines, respectively. The morphological alterations of cells under a microscope; the NLRP3 inflammasome-related markers: NLRP3, caspase-1, and ASC protein levels were detected by Western blot, IL-1β and IL-18 levels were determined by ELISA; cell migration and invasion were determined by transwell assay; and the pyroptosis levels and intracellular ROS were determined by flow cytometry analysis. Then, pretreated with 5 mM NAC for 2 h and subsequently transfected with the pcDNA3.1/CagA plasmid for 48 h, the effects of NAC pretreatment on CagA-induced NLRP3 inflammasome-related markers expression and cell pyroptosis were examined, finally assessed the effect of CagA on migration and invasion in NLRP3-silenced cells.
RESULTS: We found that Hp/CagA+ strain infection and pcDNA3.1/CagA vector transfection result in NLRP3 inflammasome activation, generation of intracellular ROS, and increased invasion and migration of gastric cancer cells. Moreover, we found that ROS inhibition via NAC effectively blocks NLRP3 activation and pyroptosis. Silencing of NLRP3 reduces the effects of CagA on gastric cancer cell migration and invasion.
CONCLUSION: Our study shows that CagA can promote the invasion and migration of gastric cancer cells by activating NLRP3 inflammasome pathway. These findings provide novel insights into the mechanism of gastric cancer induction by H. pylori.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CagA; Gastric cancer; Helicobacter pylori; Migration and invasion; NLRP3 inflammasome

Mesh:

Substances:

Year:  2021        PMID: 34854954     DOI: 10.1007/s00011-021-01522-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  1 in total

1.  The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1β production in Helicobacter pylori infected dendritic cells.

Authors:  Dong-Jae Kim; Jong-Hwan Park; Luigi Franchi; Steffen Backert; Gabriel Núñez
Journal:  Eur J Immunol       Date:  2013-07-25       Impact factor: 5.532

  1 in total
  4 in total

1.  Tofacitinib enhances IGF1 via inhibiting STAT6 transcriptionally activated-miR-425-5p to ameliorate inflammation in RA-FLS.

Authors:  Yingjie Liu; Jun Peng; Xiaochuan Xiong; Liang Cheng; Xiaobing Cheng
Journal:  Mol Cell Biochem       Date:  2022-05-10       Impact factor: 3.842

2.  NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma.

Authors:  Haitao Gu; Wensheng Deng; Yi Zhang; Yu Chang; Vishal G Shelat; Kunihiro Tsuchida; Leonardo S Lino-Silva; Zhaowen Wang
Journal:  Transl Lung Cancer Res       Date:  2022-05

3.  SHP-1/STAT3 Interaction Is Related to Luteolin-Induced Myocardial Ischemia Protection.

Authors:  Donghai Liu; Hong Luo; Chenhui Qiao
Journal:  Inflammation       Date:  2021-08-30       Impact factor: 4.092

4.  Identification of pyroptosis-related subtypes, development of a prognostic model, and characterization of tumour microenvironment infiltration in gastric cancer.

Authors:  Feng Cao; Jingtao Hu; Hongtao Yuan; Pengwei Cao; Yunsheng Cheng; Yong Wang
Journal:  Front Genet       Date:  2022-07-18       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.